Ozempic is NOT Available as an Oral Medication
Ozempic (semaglutide) is only available as a subcutaneous injection and has no oral formulation. The confusion likely stems from the existence of a different product—Rybelsus—which is oral semaglutide approved for type 2 diabetes, but this is a completely separate medication from Ozempic 1.
Ozempic Dosing (Subcutaneous Only)
Ozempic is administered as a once-weekly subcutaneous injection with the following dosing regimen 1:
Standard Dosing Schedule:
- Starting dose: 0.25 mg once weekly for 4 weeks (this is a dose escalation period, not a therapeutic dose)
- Maintenance dose: 0.5 mg once weekly after the initial 4 weeks
- Maximum dose: Can be increased to 1 mg once weekly if additional glycemic control is needed after at least 4 weeks on 0.5 mg
- Higher dose option: 2 mg once weekly is available for patients requiring further intensification
Administration Details:
- Inject subcutaneously in the abdomen, thigh, or upper arm
- Can be given any day of the week, with or without meals
- If a dose is missed, administer within 5 days; if more than 5 days have passed, skip the missed dose
- The pen delivers specific dose increments: 0.25 mg or 0.5 mg pens, and separate 1 mg pens 1
Important Distinction: Oral Semaglutide (Rybelsus)
If oral semaglutide is what you're seeking, Rybelsus is the correct product name, with dosing of:
- Starting: 3 mg daily for 30 days
- Maintenance: 7 mg daily (can increase to 14 mg daily if needed)
- Must be taken on an empty stomach with ≤120 mL water, with 30-minute wait before eating 2, 3
The oral formulation requires a specialized absorption enhancer (SNAC) and has only ~1% bioavailability compared to ~89% for subcutaneous administration 4.
Common Pitfall:
Do not confuse Ozempic (injectable) with Rybelsus (oral)—they are distinct products with different dosing, administration requirements, and approved indications, despite containing the same active ingredient (semaglutide).